BDX Stock - Becton, Dickinson and Company
Unlock GoAI Insights for BDX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $21.84B | $20.18B | $19.37B | $18.87B | $19.13B |
| Gross Profit | $9.92B | $9.13B | $8.17B | $8.48B | $8.63B |
| Gross Margin | 45.4% | 45.2% | 42.2% | 44.9% | 45.1% |
| Operating Income | $2.58B | $2.40B | $2.11B | $2.28B | $2.25B |
| Net Income | $1.68B | $1.71B | $1.48B | $1.78B | $2.09B |
| Net Margin | 7.7% | 8.4% | 7.7% | 9.4% | 10.9% |
| EPS | $5.84 | $5.88 | $4.97 | $5.93 | $6.92 |
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| September 25th 2025 | RBC Capital Mkts | Initiation | Sector Perform | $211 |
| May 22nd 2025 | Citigroup | Downgrade | Neutral | $185 |
| May 2nd 2025 | Piper Sandler | Downgrade | Neutral | $185 |
| May 2nd 2025 | Goldman | Downgrade | Neutral | $192 |
| May 2nd 2025 | Raymond James | Downgrade | Market Perform | - |
| May 1st 2025 | Wells Fargo | Downgrade | Equal Weight | - |
| May 1st 2025 | BofA Securities | Downgrade | Neutral | $190 |
| May 1st 2025 | William Blair | Downgrade | Market Perform | - |
| October 1st 2024 | Citigroup | Upgrade | Buy | $275← $255 |
| May 30th 2024 | Goldman | Initiation | Buy | $274 |
| July 24th 2023 | Raymond James | Upgrade | Outperform | $305 |
| May 30th 2023 | Morgan Stanley | Resumed | Overweight | $295 |
| May 5th 2023 | Piper Sandler | Upgrade | Overweight | $290← $260 |
| April 12th 2023 | KeyBanc Capital Markets | Upgrade | Overweight | $304 |
| January 3rd 2023 | BofA Securities | Upgrade | Buy | $290← $250 |
Earnings History & Surprises
BDXEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 29, 2026 | — | — | — | — |
Q1 2026 | Feb 4, 2026 | $2.82 | — | — | — |
Q4 2025 | Nov 6, 2025 | $3.92 | $3.96 | +1.0% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $3.40 | $3.68 | +8.2% | ✓ BEAT |
Q2 2025 | May 1, 2025 | $3.28 | $3.35 | +2.1% | ✓ BEAT |
Q1 2025 | Feb 5, 2025 | $3.00 | $3.43 | +14.3% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $3.77 | $3.81 | +1.1% | ✓ BEAT |
Q3 2024 | Aug 1, 2024 | $3.31 | $3.50 | +5.7% | ✓ BEAT |
Q2 2024 | May 2, 2024 | $2.97 | $3.17 | +6.7% | ✓ BEAT |
Q1 2024 | Feb 1, 2024 | $2.40 | $2.68 | +11.7% | ✓ BEAT |
Q4 2023 | Nov 9, 2023 | $3.42 | $3.42 | 0.0% | = MET |
Q3 2023 | Aug 3, 2023 | $2.89 | $2.96 | +2.4% | ✓ BEAT |
Q2 2023 | May 4, 2023 | $2.75 | $2.86 | +4.0% | ✓ BEAT |
Q1 2023 | Feb 2, 2023 | $2.67 | $2.98 | +11.6% | ✓ BEAT |
Q4 2022 | Nov 10, 2022 | $2.73 | $2.75 | +0.7% | ✓ BEAT |
Q3 2022 | Aug 4, 2022 | $2.49 | $2.66 | +6.8% | ✓ BEAT |
Q2 2022 | May 5, 2022 | $2.98 | $3.18 | +6.7% | ✓ BEAT |
Q1 2022 | Feb 3, 2022 | $2.86 | $3.64 | +27.3% | ✓ BEAT |
Q4 2021 | Nov 4, 2021 | $2.43 | $2.59 | +6.6% | ✓ BEAT |
Q3 2021 | Aug 5, 2021 | $2.46 | $2.74 | +11.4% | ✓ BEAT |
Latest News
BD Announces $110M Investment To Expand Production Of Prefillable Syringes, Accelerating Biologic And GLP-1 Drug Delivery And Supporting Pharmaceutical Reshoring In U.S.
📈 PositiveStifel Maintains Buy on Becton Dickinson, Raises Price Target to $215
📈 PositiveB of A Securities Maintains Neutral on Becton Dickinson, Raises Price Target to $207
➖ NeutralBD Advances Tissue Regeneration Strategy With First Phasix Mesh Prophylactic Laparotomy Reinforcement Case In Greece Following EU Indication Expansion
📈 PositiveBD Partners With University of Pennsylvania to Advance Immune Research and New Immunotherapy Treatments
📈 PositiveRBC Capital Maintains Sector Perform on Becton Dickinson, Raises Price Target to $210
➖ NeutralBD Teams Up With ChemoGLO to Improve Hazardous Drug Testing and Protect Health Care Workers
📈 PositiveBD Launches Three And Four Laser BD FACSDiscover A8 Cell Analyzer Configurations Expanding Access To Spectral Real Time Imaging Cell Analysis
📈 PositiveMorgan Stanley Maintains Overweight on Becton Dickinson, Raises Price Target to $210
📈 PositiveBecton, Dickinson And Company Files For Potential Mixed Shelf Of Up To $10B
➖ NeutralWaters Proposed Acquisition Of Becton, Dickinson and Company's Biosciences And Diagnostic Solutions Businesses Gets European Commission Approval
📈 PositiveBD Launches BD Surgiphor Surgical Wound Irrigation System In Europe
📈 PositiveBecton, Dickinson Said That CE-marked BD Onclarity HPV Assay For BD COR System And BD Viper LT System Have Been Accepted For World Health Organization List Of Prequalified In Vitro Diagnostic Products For Cervical Cancer Screening
📈 PositiveStarboard Value Gp Llc Decreases Stake In Becton Dickinson & Co By 54% To 1,207,998 Shares
📉 NegativeRBC Capital Maintains Sector Perform on Becton Dickinson, Lowers Price Target to $202
📉 NegativePiper Sandler Maintains Neutral on Becton Dickinson, Lowers Price Target to $190
➖ NeutralBDX stock has given up its prior loss. Becton, Dickinson shares were trading lower after the company missed Q4 revenue estimates.
➖ NeutralBecton, Dickinson shares are trading lower after the company missed Q4 revenue estimates.
📉 NegativeBecton Dickinson Sees FY2026 Adj EPS $14.75-$15.05 vs $14.38 Est
📈 PositiveBecton, Dickinson Q4 Adj. EPS $3.96 Beats $3.92 Estimate, Sales $5.890B Miss $5.902B Estimate
➖ NeutralFrequently Asked Questions about BDX
What is BDX's current stock price?
What is the analyst price target for BDX?
What sector is Becton, Dickinson and Company in?
What is BDX's market cap?
Does BDX pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to BDX for comparison